Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?

BACKGROUND: Cellular cholesterol efflux is a key step in reverse cholesterol transport that may impact on atherosclerotic cardiovascular risk. The process may be reliant on the availability of apolipoprotein (apo) B‐100‐containing lipoproteins to accept cholesterol from high‐density lipoprotein. Evo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Qidi, Ronca, Annalisa, Chan, Dick C., Pang, Jing, Favari, Elda, Watts, Gerald F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541635/
https://www.ncbi.nlm.nih.gov/pubmed/35294778
http://dx.doi.org/10.1111/eci.13766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541635/
https://www.ncbi.nlm.nih.gov/pubmed/35294778
http://dx.doi.org/10.1111/eci.13766

Ejemplares similares